Status:
COMPLETED
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Lead Sponsor:
University of Massachusetts, Worcester
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Metabolic Syndrome
Insulin Resistance
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitaz...
Detailed Description
Adipocytes play a crucial role in the control of metabolic homeostasis, by sequestering excess calories in the form of triglycerides, and secreting cytokines that control systemic fuel utilization. Su...
Eligibility Criteria
Inclusion
- Overweight but otherwise in good general health.
- Age 18 - 55 years.
- Normal glucose tolerance.
- Stable weight with BMI (27-44).
- Stable medication use for the preceding month.
- BP \< 150/90.
- Negative pregnancy test (\*HCG), if female and of childbearing potential.
- Practicing, and willing to continue to practice appropriate contraception throughout the study if a female of childbearing potential.
Exclusion
- Serious medical illness.
- Pregnancy.
- Tobacco use within the past 6 months.
- Prior or current treatment with a thiazolidinedione.
- Patients who have received an investigational drug in the past 30 days.
- Use of systemic corticosteroids.
- Known or suspected allergy to Rosiglitazone or any component of the preparation
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01150981
Start Date
November 1 2006
End Date
April 1 2010
Last Update
March 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMass Medical School
Worcester, Massachusetts, United States, 01655